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Abstract
Background: In	children	aged	<5	years	 in	whom	severe	 respiratory	syncytial	virus	
(RSV)	episodes	predominantly	occur,	there	are	currently	no	appropriate	standardised	
instruments	to	estimate	quality	of	life	years	(QALY)	loss.
Objectives: We	 estimated	 the	 age‐specific	 QALY	 loss	 due	 to	 RSV	 by	 developing	
a	 regression	model	which	predicts	 the	QALY	 loss	without	 the	use	of	standardised	
instruments.
Methods: We	conducted	 a	 surveillance	 study	which	 targeted	 confirmed	RSV	 epi‐
sodes	in	children	aged	<5	years	(confirmed	cases)	and	their	household	members	who	
experienced	symptoms	of	RSV	during	the	same	time	(suspected	cases).	All	partici‐
pants	were	asked	to	complete	questions	regarding	their	health	during	the	infection,	
with	 the	 suspected	 cases	 additionally	 providing	 health‐related	 quality	 of	 life	 (HR‐
QoL)	loss	estimates	by	completing	EQ‐5D‐3L‐Y	or	EQ‐5D‐3L	instruments.	We	used	
the	responses	from	the	suspected	cases	to	calibrate	a	regression	model	which	esti‐
mates	the	HR‐QoL	and	QALY	loss	due	to	infection.
Findings: For	 confirmed	 RSV	 cases	 in	 children	 under	 5	 years	 of	 age	 who	 sought	
health	care,	our	model	predicted	a	QALY	loss	per	RSV	episode	of	3.823	×	10−3 (95% 
CI	0.492‐12.766	×	10−3),	compared	with	3.024	×	10−3	(95%	CI	0.329‐10.098	×	10−3)	
for	under	fives	who	did	not	seek	health	care.	Quality	of	life	years	loss	per	episode	
was	less	for	older	children	and	adults,	estimated	as	1.950	×	10−3	(0.185‐9.578	×	10−3)	
and	1.543	×	10−3	(0.136‐6.406	×	10−3)	for	those	who	seek	or	do	not	seek	health	care,	
respectively.
Conclusion: Evaluations	of	potential	RSV	vaccination	programmes	should	consider	
their	impact	across	the	whole	population,	not	just	young	child	children.
K E Y W O R D S
cost‐effectiveness,	EQ‐5D,	health‐related	quality	of	life,	human	respiratory	syncytial	virus,	
quality‐adjusted	life	years,	respiratory	disease
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1  | INTRODUC TION
Respiratory	syncytial	virus	(RSV)	is	a	leading	cause	of	lower	respira‐
tory	tract	 infection	 in	 infants,	accounting	for	more	than	three	mil‐
lion	hospital	admissions	and	60	000	deaths	in	hospitals	for	children	
less	than	5	years	of	age	in	2015.1,2	The	health	burden	of	RSV	is	high	
because	 there	 is	 no	 licensed	 vaccine	 for	 RSV,	 leaving	 infants	 vul‐
nerable	to	infection.	However,	with	over	40	RSV	vaccine	candidates	
currently	in	preclinical	and	clinical	trials,	it	is	likely	that	a	vaccine	will	
come	to	market	 in	the	near	future.3	Decisions	regarding	the	 intro‐
duction	of	future	vaccines	will	be	informed	by	their	projected	impact	
and	cost‐effectiveness.
Cost‐effectiveness	analysis	relies	on	the	existence	of	measures	
for	morbidity	and	mortality	associated	with	RSV	episodes	routinely	
expressed	 in	 terms	 of	 quality	 of	 life	 year	 (QALY)	 loss.4	QALY	 loss	
for	 a	 single	 RSV	 episode	 is	 calculated	 by	 integrating	 the	 loss	 of	
health‐related	quality	of	 life	 (HR‐QoL)	over	the	duration	for	which	
the	symptoms	are	experienced.	Health‐related	quality	of	life	is	eval‐
uated	 through	 the	 use	of	 standardised	 and	 validated	 instruments,	
such	 as	 EuroQol's	 EQ‐5D	 that	 considers	 the	 physical,	mental	 and	
emotional	effects	of	an	illness.5	Despite	RSV	vaccine	strategy	cost‐
effectiveness	analyses	being	published,6,7	we	do	not	have	validated	
QALY	estimates	for	either	children	or	adults.8‐10	Moreover,	EQ‐5D	
methods	do	not	reliably	capture	the	HR‐QoL	in	very	young	children,	
in	whom	severe	RSV	episodes	predominantly	occur.11
In	 this	 study,	 we	 determined	 the	HR‐QoL	 loss	 due	 to	 an	 RSV	
episode	 in	 individuals	5	years	and	older	with	suspected	RSV	using	
EQ‐5D	 questionnaires.12‐14	 We	 developed	 a	 statistical	 model	 to	
predict	the	HR‐QoL	loss	as	a	function	of	responses	from	a	broader	
health	 and	 healthcare‐seeking	 questionnaire.	 We	 then	 used	 this	
statistical	model	to	estimate	QALY	loss	for	children	and	adults	over	
5	years	of	age.	Finally,	using	the	statistical	model	parameterised	with	
responses	 from	 the	 broader	 health	 and	 healthcare‐seeking	 ques‐
tionnaire	administered	to	caregivers	of	children	aged	younger	than	
five	with	recently	confirmed	RSV	infection,	we	calculated	the	QALY	
loss	per	RSV	episode	for	children	less	than	five.
2  | METHODS
2.1 | Study recruitment
During	 the	 2016‐17	 RSV	 season,	 confirmed	 cases	 of	 RSV	 in	 chil‐
dren	under	 the	age	of	5	years	 from	the	previous	 two	weeks	were	
extracted	on	dates	13th	December,	25th	December	2016	and	3rd	
January	 2017	 from	 the	 Public	 Health	 England	 (PHE)	 Respiratory	
DataMart	surveillance	(RDMS)	system.15	For	all	the	confirmed	cases	
for	whom	 name,	 date	 of	 birth	 and	National	Health	 Service	 (NHS)	
number	 were	 provided,	 home	 addresses	 were	 obtained	 from	 the	
PHE	Patient	Demographic	Service.	For	all	these	home	addresses,	a	
questionnaire	pack	addressed	to	the	parent	or	guardian	of	the	con‐
firmed	case	was	sent	the	day	after	its	extraction	date	from	the	PHE	
RDMS	 system.	 Each	 questionnaire	 pack	 consisted	 of	 three	 ques‐
tionnaires,	 an	 information	 sheet	 and	 a	 stamped	 addressed	 return	
envelope.	The	Index	Questionnaire	requested	information	about	the	
recent	RSV	episode	in	the	confirmed	case.	The	other	two	question‐
naires	requested	information	about	suspected	RSV	episodes	in	older	
household	 members,	 those	 aged	 5‐14	 years	 (5‐14	 Questionnaire)	
and	 those	 aged	 15	 years	 or	 older	 (15+	Questionnaire).	 Suspected	
RSV	cases	were	defined	as	persons	who	share	a	household	with	the	
confirmed	 case	 and	who	 experienced	 an	 onset	 of	 RSV‐like	 symp‐
toms	(runny	or	blocked	nose,	fever,	coughing,	and/or	a	sore	throat)	
between	5	days	before	and	5	days	after	the	onset	of	symptoms	in	
the	confirmed	case.16,17
2.2 | Questionnaire information
The	Index	Questionnaire	was	completed	by	a	parent	or	guardian	on	
behalf	of	 the	confirmed	case,	 the	5‐14	Questionnaire	on	behalf	of	
or	by	the	child	themselves	and	the	15+	Questionnaire	by	the	ado‐
lescent	or	adult.	The	Index	Questionnaire	requested	information	on	
(a)	the	age	of	the	child,	 (b)	the	confirmed	case's	symptoms	(runny/
blocked	nose,	fever,	coughing,	sore	throat),	(c)	the	healthcare‐seek‐
ing	behaviour	 (no	healthcare	sought,	contacted	or	visited	GP,	visit	
to	Accident	and	Emergency	department,	admission	to	hospital),	 (d)	
coughing	 severity	 (mild/no	 coughing,	 severe	 coughing)	 and	 (e)	 a	
Visual	Analogue	Scale	(VAS)	for	the	worst	day	of	the	recent	 infec‐
tion	and	the	day	of	questionnaire	completion.	A	VAS	was	presented	
for	health	from	0	(worst	health)	to	100	(best	health)	for	both	days	
and	the	difference	between	the	VAS	scores	was	defined	as	the	VAS	
score	loss	due	to	an	RSV	episode.	In	addition	to	the	questions	asked	
in	 the	 Index	Questionnaire,	 the	 5‐14	 and	 the	 15+	Questionnaires	
also	asked	(f)	the	time	taken	off	school/work	due	to	symptoms	(pro‐
ductivity)	 and	 (g)	EuroQol	EQ‐5D‐3L‐Y12‐14	 (for	5‐14	year	olds)7 or 
EQ‐5D‐3L12,13	(for	15+	year	olds)	questionnaires	to	determine	HR‐
QoL	weight	at	baseline	and	on	the	worst	day	of	suspected	RSV	infec‐
tion.	See	Appendix	S1	for	full	questionnaire	packs.
The	EuroQol	ED‐5D‐3L‐Y12‐14	and	EQ‐5D‐3L12,13	questionnaires	
use	a	UK‐specific	time	trade‐off	scoring	tariff	to	determine	the	HR‐
QoL	weight	according	to	five	dimensions:	mobility,	self‐care,	usual	
activities,	pain/discomfort	and	anxiety/depression.	We	refer	to	this	
HR‐QoL	weight	on	the	worst	day	of	infection	as	the	peak	HR‐QoL	
weight	from	the	data	and	the	difference	in	the	HR‐QoL	weights	be‐
tween	the	baseline	and	the	worst	day	of	infection	as	the	peak	HR‐
QoL	loss	from	the	data.
2.3 | Statistical model to estimate HR‐QoL
EQ‐5D	questionnaires	are	not	validated	for	children	under	5	years	of	
age	so	we	cannot	obtain	estimates	for	the	peak	HR‐QoL	loss	from	
the	 data	 in	 the	 confirmed	 cases.	 Therefore,	 using	 the	 responses	
from	the	suspected	cases,	we	fitted	a	 regression	model	 to	predict	
the	 (model‐estimated)	 peak	 HR‐QoL	 loss,	 as	 a	 function	 of	 ques‐
tionnaire	 response	 variables:	 age	 (5‐14	years,	 15	 years	 and	older),	
coughing	 severity,	 healthcare‐seeking	 behaviour,	 productivity	 and	
VAS	score	loss	(Appendix	S2	Section	1).	To	fit	the	regression	model,	
we	only	included	responses	from	suspected	cases	which,	in	addition	
     |  3HODGSON et al.
to	 providing	 answers	 to	 the	 aforementioned	 response	 variables,	
completed	all	five	dimensions	of	health	status	in	their	EQ‐5D	ques‐
tionnaires.	 To	 assess	 the	 accuracy	 of	 the	 fitted	 regression	model,	
we	compared	the	peak	HR‐QoL	loss	from	the	response	data	to	the	
model‐estimated	 peak	 HR‐QoL	 loss	 value	 from	 the	 fitted	 model.	
To	determine	the	model‐estimated	peak	HR‐QoL	loss	in	confirmed	
cases,	we	only	 included	confirmed	questionnaire	 responses	which	
provided	answers	to	coughing	severity,	productivity	loss,	healthcare‐
seeking	behaviour	and	VAS	score	loss.	All	analysis	was	performed	in	
r	(v.	3.3.2),	and	plotting	was	performed	in	MatheMatica	(v.	10.3.0.0).	
Full	details	of	the	statistical	model	are	provided	in	Appendix	S2.
2.4 | Quality‐adjusted life year (QALY) loss due to 
an RSV episode
We	estimated	 each	 respondent's	QALY	 loss	 by	multiplying	 their	
model‐estimated	peak	HR‐QoL	 life	 loss	 by	 (a)	 a	 pooled	duration	
of	coughing	distribution	and	(b)	a	fixed	scaling	factor	for	disease	
severity	throughout	the	illness.	We	estimated	the	pooled	cough‐
ing	duration	distribution	separately	for	under	fives,	5‐14	years	and	
15+	years,	and	for	whether	there	was	severe	coughing	(Appendix	
S2,	Section	4).	In	estimating	the	pooled	coughing	duration	distri‐
butions,	we	excluded	responses	that	did	not	indicate	a	duration	of	
coughing	and	those	that	indicated	a	duration	of	more	than	22	days	
as	this	is	longer	than	the	maximum	duration	of	RSV	symptoms	re‐
ported	in	previous	studies.16	We	estimated	the	scaling	factor	for	
disease	severity	using	daily	EQ‐5D	questionnaires	from	individu‐
als	 participating	 in	 the	 Flu	Watch	 study18	 (Appendix	 S2	 Section	
3).	Due	to	study	design,	we	did	not	collect	data	on	HR‐QoL	 loss	
in	children	under	the	age	of	5	years	who	did	not	seek	health	care.	
Therefore,	to	estimate	the	QALY	loss	for	that	group,	we	assumed	
that	 the	 ratio	 of	QALY	 loss	 for	 people	who	 seek	 health	 care	 to	
those	that	do	not	is	independent	of	age.
2.5 | Annual QALY loss due to RSV in England
We	estimated	the	annual	QALY	loss	for	individuals	under	five	and	over	
five	years	old	due	to	healthcare‐seeking	RSV	infections	in	England	by	
multiplying	our	per‐episode	age‐specific	estimate	of	QALY	loss	with	
a	previous	estimate	of	the	age‐specific	annual	number	of	GP	consul‐
tations	and	hospital	admissions	due	to	RSV	in	England.6,19
2.6 | Ethics approval
In	 accordance	 with	 The	 Health	 Service	 (Control	 of	 Patient	
Information)	Regulations	2002	No.	1438	Section	251	Regulation	3,	
Public	Health	England	may	process	confidential	patient	information	
with	 a	 view	 to	monitoring	 and	managing;	 outbreaks	 of	 communi‐
cable	disease;	 incidents	of	exposure	 to	communicable	disease	and	
the	delivery,	efficacy	and	safety	of	immunisation	programmes.20	All	
questionnaires	 that	were	 returned	 from	households	 and	 stored	 at	
PHE	had	no	identifying	information.
3  | RESULTS
3.1 | Questionnaire responses
We	sent	out	770	questionnaire	packs	between	15	December	2016	
and	 4	 January	 2017	 and	 received	 122	 responses	 by	 28	 February	
2017	(response	rate	of	16%).	We	found	that,	when	stratified	by	year	
of	age,	the	age	distribution	of	the	confirmed	cases	who	responded	
was	similar	to	the	age	distribution	of	the	contacted	confirmed	RSV	
index	cases.	However,	when	stratified	by	month	of	age	in	the	first	
year	of	 life,	we	oversampled	 infants	aged	3‐4	months	old	and	un‐
dersampled	 infants	aged	1‐2	months	old	 (Figure	1A,B).	 In	 the	122	
households,	 suspected	cases	were	 reported	 in	33	 (27.0%)	persons	
aged	5‐14	years	old	and	54	(44.2%)	of	persons	aged	15	years	or	older.
After	selecting	questionnaire	responses	according	to	the	inclu‐
sion	criteria,	we	determined	the	model‐estimated	peak	HR‐QoL	loss	
for	108/122	(88.5%)	of	confirmed	cases	in	children	less	than	5	years	
of	age,	and	for	21/33	(63.6%)	and	40/54	(74.1%)	of	suspected	cases	
aged	5‐14	years	 and	15	years	 and	older,	 respectively.	Duration	of	
coughing	 was	 provided	 for	 98/122	 (80.3%)	 and	 43/87	 (49.4%)	 of	
confirmed	and	suspected	cases,	respectively.
In	 the	 questionnaire	 responses	 from	 the	 suspected	 cases,	 we	
found	that	21/33	(63.6%)	of	children	aged	5‐14	years	old,	and	43/54	
(79.9%)	of	persons	aged	15	years	and	older	did	not	seek	health	care	
due	of	their	suspected	RSV	episode	(Table	1).	Further,	we	found	that	
17/33	 (51.5%)	 children	 aged	 5‐14	 years	 took	 time	 off	 school	 and	
F I G U R E  1  Age	of	confirmed	RSV	samples	in	PHE	database	
(N	=	770,	black)	and	of	the	returned	questionnaires	for	analysis	
(N	=	122,	grey)
( )
<
Positive RSV samples
Questionnaire respondents
(A)
( )
<
(B)
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9/54	(16.6%)	of	persons	aged	15	years	and	older	took	time	off	work	
or	school	due	to	their	suspected	RSV	infection,	both	with	a	median	
time	off	of	2	days	(range	1‐10	days)	(Table	1).	The	EQ‐5D‐Y	question‐
naires	suggested	that	for	children	aged	5‐14	years	old	RSV	mostly	
affected	 usual	 activities	 (72%),	 caused	 pain/discomfort	 (76%)	 and	
anxiety/depression	(84%).	The	EQ‐5D‐3L	responses	for	respondents	
aged	15	years	and	older	suggested	similar	results	with	RSV	affect‐
ing	 respondents'	 usual	 activities	 (54.2%),	 causing	 pain/discomfort	
(36.0%)	and	anxiety	and	depression	 (32.0%)	 (Figure	2).	Converting	
these	EQ‐5D	and	EQ‐5D‐3L	 responses	 using	 the	UK	TTO	 scoring	
tariff,	 the	median	peak	HR‐QoL	weight	 from	 the	data	 for	children	
aged	5‐14	years	old	and	persons	15	years	and	older	was	0.689	(range	
−0.170‐1.000)	 and	 0.752	 (range	 −0.166	 to	 1.000),	 respectively	
(Table	S2).	These	weights	 led	 to	a	median	peak	HR‐QoL	 loss	 from	
the	data	of	0.456	 (range	0.0‐1.170)	 and	0.358	 (range	0‐0.998)	 for	
5‐14	and	15	years	and	older,	respectively.	As	there	was	no	significant	
difference	between	the	peak	HR‐QoL	 loss	from	the	data	between	
5	 and	 14	 years	 old	 and	 persons	 15	 years	 (Kolmogorov‐Smirnov	
 
Aged 0‐4 ya 
(n = 122) (%)
Aged 5‐14 y 
(n = 33) (%)
Aged 15 y and over 
(n = 54) (%)
Symptoms
Runny/blocked	nose 96	(78.7) 28	(84.8) 43	(79.6)
Fever 70	(57.4) 18	(54.5) 22	(40.7)
Coughing 110	(90.2) 27	(81.8) 51	(94.4)
Sore	throat 36	(29.5) 17	(51.5) 38	(70.4)
Coughing	severity
No	effect	on	daily	activities 16	(13.1) 10	(30.3) 8	(14.8)
Mild	effect	on	daily	activities 34	(27.9) 15	(45.5) 32	(59.3)
Severe	effect	on	daily	activities 93	(76.2) 4	(12.1) 8	(14.8)
Coughing	severity	duration
No	effect	on	daily	activities	
(median,	range)
4	d	(1‐14) 10	d	(10‐10) 14.5	d	(1‐28)
Mild	effect	on	daily	activities	
(median,	range)
3.5	d	(1‐14) 3	d	(1‐9) 5.5	d	(1‐28)
Severe	effect	on	daily	activities	
(median,	range)
6.5	d	(1‐35) 3	d	(1‐4) 7	d	(3‐10)
Healthcare‐seeking	behaviour
Phone/email	NHS	111/NHS	24/
NHS	choices
39	(32.0) 2	(6.1) 2	(3.7)
Phone/email	GP—response	from	
the	receptionist
20	(16.4) 2	(6.1) 2	(3.7)
Phone/email	GP—response	from	
the	doctor	or	nurse
20	(16.4) 2	(6.1) 2	(3.7)
Visit	a	GP	or	nurse 83	(68.0) 10	(30.3) 10	(18.5)
Visit	A&E	department	(including	
out	of	hours	service)
71	(58.2) 3	(9.1) 1	(1.9)
Admitted	to	hospital 103	(84.4) 1	(3.0) 1	(1.9)
None 0	(0.0) 21	(63.6) 43	(79.6)
Productivity
Individuals	reporting	taking	time	
off	work	or	school
— 17	(51.5) 9	(16.7)
Duration	of	time	off	work	or	
school	(median,	range)
— 2	d	(1‐10) 2	d	(1‐7)
VAS	score	loss
Baseline	(median,	range) 90	(30‐100) 95	(10‐100) 95	(50‐100)
Worst	day	(median,	range) 20	(0‐85) 50	(5‐85) 50	(0‐90)
Loss	(median,	range) 65	(10‐100) 38	(0‐90) 35	(10‐85)
Note: Numbers	in	parentheses	are	the	percentage	unless	otherwise	stated.
Abbreviation:	VAS,	visual	analogue	scale.
aConditional	on	ascertaining	a	confirmed	case	through	GP/hospitalisation.	
TA B L E  1  Summary	of	index,	5‐14	and	
15+	Questionnaire	responses
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test,	P	=	 .291),	all	HR‐QoL	and	QALY	results	were	pooled	for	ages	
5+	years	for	further	analysis.
For	individuals	seeking	health	care,	we	found	that	cases	in	chil‐
dren	under	 the	 age	of	5	 years	were	more	 severe	when	 compared	
with	suspected	cases	in	persons	aged	5	years	and	older	as	evidenced	
by	a	higher	VAS	score	loss	(median	65	vs	40)	and	the	proportion	of	
persons	with	severe	coughing	(0.76	vs	0.18).
3.2 | Model‐estimated peak HR‐QoL loss
Using	 a	 backwards	 stepwise	 regression	 approach,	 our	 statistical	
model	found	that	the	peak	HR‐QoL	loss	from	the	data	was	parsimoni‐
ously	predicted	by	three	factors:	the	VAS	score	loss,	whether	health	
care	was	sought	and	the	presence	of	severe	coughing	(Appendix	S2,	
Section	2	and	Figures	S2‐S8).
Our	statistical	model	predicted	 the	model‐estimated	peak	HR‐
QoL	 loss	 in	 suspected	 cases	 aged	 5	 years	 and	 older	who	 did	 and	
did	not	 seek	health	care	as	0.616	 (95%	CI	0.155‐1.371)	and	0.405	
(95%	CI	0.111‐1.137),	respectively.	We	found	that	the	questionnaire	
data	were	well	predicted	by	the	model,	with	no	evidence	to	suggest	
the	peak	HR‐QoL	 loss	 from	 the	data	and	 the	model	was	different	
(Kolmogorov‐Smirnov	test,	P	=	 .111,	Figure	3).	Applying	our	statis‐
tical	model	to	those	under	five	for	whom	HR‐QoL	loss	could	not	be	
directly	estimated,	we	found	a	model‐estimated	peak	HR‐QoL	loss	
of	 0.820	 (95%	CI	 0.222‐1.450,	 Table	2;	 Tables	 S2	 and	S3).	 Finally,	
assuming	the	ratio	of	HR‐QoL	loss	for	healthcare‐seeking	cases	to	
non‐health‐seeking	 cases	 is	 independent	 of	 age,	 we	 estimated	 a	
model‐estimated	peak	HR‐QoL	loss	for	under	fives	as	0.539	(95%	CI	
0.144‐0.952,	Table	2;	Tables	S2	and	S3).
3.3 | Quality‐adjusted life years loss
The	daily	RSV	HR‐QoL	weights	from	Flu	Watch18	suggest	that	for	
the	first	half	of	symptom	duration,	the	HR‐QoL	weight	decreases	
F I G U R E  2  Responses	from	the	
EQ‐5D‐3L‐Y	and	EQ‐5D‐3L	questionnaires	
on	the	day	of	completion	(Base)	and	the	
worst	day	of	health	during	a	suspected	
infection	for	respondents	aged	5‐14	y	old	
(top)	and	15+	y	old	(bottom)
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linearly	 to	 its	 minimum	 before	 linearly	 rebounding	 to	 baseline	
health.	There	 is	no	reported	reduction	of	HR‐QoL	weight	during	
the	second	half	of	symptom	duration.	To	account	for	the	changing	
severity	of	symptoms	across	the	entire	RSV	episode,	we	calculated	
the	weighted	HR‐QoL	 loss	 by	multiplying	 the	HR‐QoL	 loss	 by	 a	
constant	scaling	factor	of	0.25	(Appendix	S2	Section	3).	Finally,	to	
calculate	the	estimated	QALY	loss	per	RSV	episode,	we	multiplied	
the	 weighted	 HR‐QoL	 loss	 per	 RSV	 episode	 by	 the	 duration	 of	
symptoms	reported	in	our	questionnaire	responses	(Appendix	S2	
Section	4).	The	duration	of	symptoms	in	children	aged	5‐14	years	
was	shorter	 (median	3	days	 [range	1‐10])	 than	both	 the	duration	
of	symptoms	in	children	under	5	years	old	(median	5	days	[range	
1‐21])	and	in	persons	aged	15	years	and	older	(median	5	days	[range	
1‐21])	(Figure	S10).	This	calculation	led	to	an	estimated	QALY	loss	
per	healthcare‐seeking	RSV	episode	in	children	less	than	5	years	
old	of	3.823	×	10−3	(95%	CI	0.492‐12.766	×	10−3,	Table	2;	Tables	
S2	and	S3)—approximately	twice	that	for	persons	aged	5	years	and	
older	 (1.950	×	 10−3	 (95%	CI	 (0.185‐9.578	×	 10−3))).	 For	 individu‐
als	who	did	not	seek	health	care,	the	QALY	loss	per	RSV	episode	
was	 3.024	 ×	 10−3	 (95%	 CI	 0.329‐10.098	 ×	 10−3)	 for	 under	 fives	
and	1.543	×	10−3	 (95%	CI	0.136‐6.406	×	10−3)	 for	 those	5	years	
and older.
3.4 | Healthcare‐seeking and total disease burden
The	 total	 number	 of	 annual	GP	 consultations	 and	 hospital	 admis‐
sions	 due	 to	 RSV	 in	 England	 is	 855	 000	 and	 375	 000‐383	 000	
for	persons	aged	5	years	and	older	and	 less	 than	5	years,	 respec‐
tively.6,19	Combining	 these	numbers	with	our	QALY	 loss	estimates	
for	individuals	seeking	health	care	in	England	resulted	in	a	mean	an‐
nual	QALY	loss	of	3120‐3141,	54%	of	which	is	attributable	to	those	
5	years	and	older.
Our	 questionnaire	 responses	 indicated	 that	 25%	 of	 individu‐
als	aged	5	years	and	older	seek	health	care	during	an	RSV	episode	
(Table	1).	Using	this	proportion,	we	estimated	that	there	are	approx‐
imately	2.6	million	symptomatic	RSV	infections	in	England	annually	
that	will	 not	be	 captured	 in	 a	healthcare	 surveillance	 system.	The	
mean	annual	QALY	loss	associated	with	these	non‐healthcare‐seek‐
ing	episodes	for	persons	5	years	and	older	is	around	4011,	approxi‐
mately	29%	of	the	QALY	loss	in	this	age	group.
4  | DISCUSSION
In	this	study,	we	quantified	the	quality	of	life	(QALY)	loss	associated	
with	RSV	episodes.	For	children	over	5	years	old	and	adults,	we	de‐
veloped	a	statistical	model	that	found	that	the	QALY	loss	can	be	ac‐
curately	predicted	by	whether	there	was	severe	coughing,	whether	
health	 care	was	 sought	 and	Visual	Analogue	Scale	 score	 loss.	We	
used	our	novel	statistical	model	 to	evaluate	the	QALY	 loss	 in	chil‐
dren	 under	 5	 years	 old,	 in	whom	 the	majority	 of	 severe	RSV	 epi‐
sodes	occur	but	for	whom	QALY	loss	cannot	be	estimated	directly.	
For	those	who	seek	health	care,	we	found	the	QALY	loss	in	children	
under	the	age	of	5	years	is	3.823	×	10−3	(95%	CI	0.492‐12.766),	double	
that	for	those	5	years	and	older	(1.950	×	10−3	(95%	CI	0.185‐9.578)).	
However,	combining	these	estimates	with	the	reported	number	of	
RSV‐associated	GP	consultations	and	hospital	 admissions,	we	 find	
that	54%	of	 the	annual	QALY	burden	 in	England	 is	attributable	 to	
those	over	5	years	old.
Our	study	has	some	limitations.	First,	because	the	confirmed	
cases	were	recruited	 into	the	study	conditional	on	them	seeking	
health	care,	we	could	not	directly	estimate	the	QALY	loss	in	chil‐
dren	less	than	5	years	old	who	did	not	seek	health	care	from	our	
statistical	model.	To	overcome	this	limitation,	we	assume	that	the	
F I G U R E  3  The	peak	HR‐QoL	loss	from	the	EQ‐5D	questionnaires	(dark	grey)	and	estimated	using	the	statistical	model	(light	grey).	The	
dashed	line	shows	the	mean,	and	solid	thin	lines	indicate	the	upper	and	lower	95%	confidence	interval
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ratio	of	QALY	loss	for	people	over	5	years	who	do	not	seek	health	
care	 to	 those	 that	do	 is	 the	same	 independent	of	age.	However,	
using	 this	 ratio	may	 overestimate	 the	QALY	 loss	 of	 non‐health‐
care‐seeking	cases	in	children	less	than	5	years	of	age,	as	health‐
care‐seeking	cases	in	persons	aged	5	years	and	older	are	generally	
milder	 than	 healthcare‐seeking	 confirmed	 cases	 in	 infants	 less	
than	5	years	old	 (with	decreases	 in	VAS	score	 loss,	coughing	se‐
verity,	 and	 the	 proportion	 admitted	 to	 hospital).	 To	 collect	 data	
directly	on	the	QALY	loss	in	children	under	five	who	do	not	seek	
health	 care	 would	 require	 a	 much	 larger	 and	 more	 intensive	
community‐based	study	with	frequent	testing	throughout	an	RSV	
season.	Second,	suspected	cases	may	have	experienced	non‐RSV	
respiratory	 disease.	However,	 previous	 studies	 have	 shown	 that	
around	 50%	 of	 households	 experience	 a	 secondary	 infection	 in	
either	siblings	or	parents	during	the	same	time	as	an	infection	in	
the	infant;	therefore,	it	is	reasonable	to	assume	that	the	majority	
of	suspected	cases	are	in	fact	RSV.21	Finally,	completing	question‐
naires	 some	 days	 after	 symptoms	may	 be	 subject	 to	 recall	 bias.	
Our	 estimates	 for	 the	 peak	 HR‐QoL	 life	 loss	 for	 persons	 aged	
15	 years	 and	 older	 (0.452	 (95%	CI	 0.177‐1.222))	 are	 larger	 than	
the	 peak	 HR‐QoL	 loss	 estimated	 in	 the	 Flu	Watch	 study	 (range	
0.107‐0.309);	however,	this	latter	estimate	may	be	imprecise	due	
to	the	small	sample	size.
Our	study	is	the	first	to	estimate	the	QALY	loss	due	to	acute	RSV	
infection.	Two	previous	studies	have	also	estimated	the	HR‐QoL	due	
to	RSV	infection	both	of	which	suffer	from	shortcomings.	The	first	
study	a	time	trade‐off	study	which	estimated	HR‐QoL	loss	using	re‐
sponses	from	participants	about	a	hypothetical	illness	that	they,	or	
their	child,	had	not	experienced.8,9	Unlike	this	study,	we	calculated	
the	HR‐QoL	 loss	 for	 people	who	 have	 had,	 or	 suspected	 to	 have	
had,	 a	 recent	RSV	 infection.	The	 second	 study	estimated	 the	HR‐
QoL	using	EQ‐5D	questionnaires	 for	children	with	RSV‐associated	
sequelae.10	Sequelae	included	chronic	conditions	such	as	persistent	
coughing	and/or	wheeze	so	HR‐QoL	loss	estimates	are	likely	to	dif‐
fer	substantially	 from	those	associated	with	acute	RSV	symptoms.	
For	accurate	evaluations,	we	recommend	that	future	cost‐effective‐
ness	analyses	use	directly	obtained	HR‐QoL	loss	estimates	for	RSV	
episodes,	such	as	those	presented	in	this	paper,	 in	addition	to	HR‐
QoL	loss	associated	with	sequelae.
We	present	a	novel	statistical	model	to	estimate	QALY	loss	due	
to	 RSV	 in	 young	 children	 for	 whom	 standardised	 instruments	 for	
deriving	HR‐QoL	estimates	are	not	appropriate.	Thus,	our	method	
leverages	 the	 use	 of	 standardised	 instruments	 such	 as	 EQ‐5D	 to	
quantify	QALY	loss	using	more	easily	measurable	variables	of	infec‐
tion	in	young	children.	Our	method	could	be	applied	to	calculate	HR‐
QoL	for	infectious	diseases	for	which	the	burden	of	severe	disease	is	
found	in	children	younger	than	5	years.
Our	 RSV‐related	 QALY	 loss	 estimate	 for	 people	 aged	 5	 years	
and	over	is	consistent	to	the	estimates	of	a	prospective	study	that	
estimated	QALY	loss	across	people	of	all	ages	with	non‐confirmed	
Influenza	who	reported	 influenza‐like	 illness	 (ILI)	 (mean	2.6	×	10−3 
(range	 −69.2	 to	 39.7	 ×	 10−3)).22	 Similarly,	 for	 the	 under	 fives,	 our	
estimates	are	similar	to	non‐influenza	episodes	who	suffer	ILI	who	
present	at	a	hospital	or	GP	(4.0	×	10−3	(range	3.4‐4.6	×	10−3)).23 In 
contrast,	we	find	that	our	QALY	loss	estimates	for	RSV	episodes	in	
the	under	 fives	who	 seek	health	 are	 less	 severe	 than	hospitalised	
influenza	episodes,	(QALY	loss	of	6.0	×	10−3	(range	5.1‐6.9	×	10−3)).23 
These	 comparisons	 suggest	 that,	 although	 influenza	 has	 a	 higher	
QALY	loss	per	episode,	the	QALY	loss	due	to	an	RSV	episode	is	com‐
parable	to	previous	QALY	loss	estimates	for	persons	with	general	ILI.
We	estimated	that	54%	of	the	QALY	loss	associated	with	health‐
care‐seeking	episodes	was	attributable	to	 individuals	aged	5	years	
and	 older.	 This	 result	 suggests	 that	 neglecting	QALY	 loss	 in	 older	
TA B L E  2  HR‐QoL,	QALD	and	QALY	loss	for	the	confirmed	
cases	in	children	less	than	5	y	of	age,	and	in	the	suspected	cases	in	
children 5 y and older
 Under 5 y of agea
Five years of 
age and older
Model‐estimated	peak	HR‐QoL	loss	(Mean	and	95%	CI)
Coughing	severity
None	or	mild 0.499	(0.148‐1.482) 0.382 
(0.111‐1.113)
Severe 0.878	(0.344‐1.443) 0.785 
(0.280‐1.368)
Healthcare‐seeking	behaviour
None 0.539	(0.144‐0.952)b 0.405 
(0.111‐1.137)
Seek	healthcare 0.820	(0.222‐1.450) 0.616 
(0.155‐1.371)
QALD	loss	(Mean	and	95%	CI)
Coughing	severity
None	or	mild 0.845	(0.097‐3.292) 0.528 
(0.050‐2.167)
Severe 1.496	(0.221‐4.841) 1.103 
(0.126‐4.149)
Healthcare‐seeking	behaviour
None 1.00	(0.141‐3.652)b 0.565 
(0.049‐2.349)
Seek	health	care 1.391	(0.179‐4.617) 0.866 
(0.071‐3.508)
QALY	loss	(Mean	and	95%	CI)
Coughing	severity
None	or	mild 2.336	×	10−3 
(0.269‐9.255)
1.448	×	10−3 
(0.135‐5.928)
Severe 4.098	×	10−3 
(0.624‐13.141)
2.990	×	10−3 
(0.346‐11.387)
Healthcare‐seeking	behaviour
None 3.024	×	10−3 
(0.329‐10.098)b
1.543	×	10−3 
(0.136‐6.406)
Seek	health	care 3.823	×	10−3 
(0.492‐12.766)
1.950	×	10−3 
(0.185‐9.578)
aConditional	on	ascertaining	a	confirmed	case	through	GP/
hospitalisation.	
bEstimated	by	assuming	the	proportional	reduction	in	HR‐QoL	loss	and	
QALY	loss	between	those	who	seek	health	care	and	those	who	do	not	is	
the	same	as	observed	in	suspected	infections	in	persons	over	5	y	of	age.	
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children	 and	 working‐age	 adults	 might	 substantially	 underesti‐
mate	 the	 impact	 of	 a	 potential	 RSV	 vaccine	 programme.	 Further,	
our	 results	 are	 consistent	with	 previous	 studies	 that	 suggest	 that	
RSV	is	characterised	by	high	 levels	of	household	transmission.21,24 
Together,	these	data	suggest	that	integrating	transmission	models—
that	capture	both	the	direct	and	indirect	effects	of	immunisation—
into	economic	evaluations	will	be	crucial	to	accurately	estimate	the	
impact	of	potential	vaccine	programmes.
From	our	 questionnaires,	we	 are	 unable	 to	 estimate	 the	 pro‐
portion	of	healthcare	seeking	in	children	younger	than	5	years	with	
symptomatic	RSV.	However,	we	expect	this	proportion	to	be	higher	
than	the	25%	reported	in	those	aged	5	years	and	older	for	two	rea‐
sons:	 infections	 in	 infants	are	generally	more	severe,	with	higher	
rates	 of	 symptomatic	 infections25	 and	 a	 tendency	 for	 increased	
parental	 healthcare	 seeking	 for	 infants	 and	 toddlers.	 However,	
the	healthcare‐seeking	behaviour	for	both	children	and	adults	will	
likely	depend	on	the	country	and	we	suggest	caution	in	translating	
our	total	RSV	burden	estimates	for	England	to	other	countries.
In	 summary,	we	estimated	 the	QALY	 loss	due	 to	an	RSV	epi‐
sode	in	confirmed	cases	in	children	less	than	5	years	old	and	sus‐
pected	 cases	 in	 persons	 aged	5	 years	 and	older.	Despite	 severe	
RSV	being	associated	with	infants,	we	found	that	RSV	infections	
in	 individuals	aged	5	years	and	older	account	for	54%	of	the	an‐
nual	 QALY	 loss	 attributable	 to	 healthcare‐seeking	 episodes	 in	
England.	Consequently,	economic	evaluations	of	potential	vaccine	
programmes	should	consider	the	effect	on	reducing	incidence	not	
only	where	the	severe	disease	burden	 lies,	but	across	 the	whole	
population.
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